Legal & General Group PLC Alkermes Plc. Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Alkermes Plc. stock. As of the latest transaction made, Legal & General Group PLC holds 581,188 shares of ALKS stock, worth $16.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
581,188
Previous 581,188 -0.0%
Holding current value
$16.4 Million
Previous $16.3 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$23.01 - $28.55 $180,927 - $224,488
7,863 Added 1.37%
581,188 $16.3 Million
Q2 2024

Aug 14, 2024
SELL
$23.21 - $27.24 $231,659 - $271,882
-9,981 Reduced 1.71%
573,325 $13.8 Million
Q1 2024

May 14, 2024
SELL
$26.4 - $32.56 $740,731 - $913,568
-28,058 Reduced 4.59%
583,306 $15.8 Million
Q4 2023

Feb 15, 2024
BUY
$23.37 - $28.68 $7.15 Million - $8.78 Million
306,015 Added 100.22%
611,364 $17 Million
Q3 2023

Nov 14, 2023
BUY
$27.17 - $31.97 $36,108 - $42,488
1,329 Added 0.44%
305,349 $8.55 Million
Q2 2023

Aug 14, 2023
SELL
$28.34 - $33.63 $282,238 - $334,921
-9,959 Reduced 3.17%
304,020 $9.52 Million
Q1 2023

May 15, 2023
BUY
$25.31 - $29.02 $215,286 - $246,844
8,506 Added 2.78%
313,979 $8.85 Million
Q4 2022

Feb 14, 2023
BUY
$21.94 - $26.24 $127,888 - $152,952
5,829 Added 1.95%
305,473 $7.98 Million
Q3 2022

Nov 14, 2022
SELL
$22.0 - $31.87 $168,916 - $244,697
-7,678 Reduced 2.5%
299,644 $6.69 Million
Q2 2022

Aug 22, 2022
BUY
$26.4 - $30.54 $14,150 - $16,369
536 Added 0.17%
307,322 $9.16 Million
Q1 2022

May 16, 2022
BUY
$23.07 - $27.99 $19,263 - $23,371
835 Added 0.27%
306,786 $8.07 Million
Q4 2021

Feb 14, 2022
BUY
$21.47 - $32.08 $234,323 - $350,121
10,914 Added 3.7%
305,951 $7.12 Million
Q3 2021

Nov 15, 2021
BUY
$23.37 - $32.13 $829,074 - $1.14 Million
35,476 Added 13.67%
295,037 $9.1 Million
Q2 2021

Aug 12, 2021
BUY
$18.78 - $25.15 $358,698 - $480,365
19,100 Added 7.94%
259,561 $6.37 Million
Q1 2021

May 17, 2021
BUY
$18.21 - $23.2 $95,729 - $121,962
5,257 Added 2.24%
240,461 $4.49 Million
Q4 2020

Feb 12, 2021
SELL
$15.39 - $22.1 $285,299 - $409,689
-18,538 Reduced 7.31%
235,204 $4.69 Million
Q3 2020

Nov 13, 2020
SELL
$16.16 - $20.66 $132,188 - $168,998
-8,180 Reduced 3.12%
253,742 $4.2 Million
Q2 2020

Aug 14, 2020
BUY
$13.31 - $19.41 $125,979 - $183,715
9,465 Added 3.75%
261,922 $5.08 Million
Q1 2020

May 14, 2020
SELL
$13.06 - $21.24 $92,908 - $151,101
-7,114 Reduced 2.74%
252,457 $3.64 Million
Q4 2019

Feb 13, 2020
SELL
$17.29 - $21.74 $5.04 Million - $6.34 Million
-291,724 Reduced 52.92%
259,571 $5.3 Million
Q3 2019

Nov 13, 2019
SELL
$19.51 - $24.28 $7.22 Million - $8.98 Million
-369,826 Reduced 40.15%
551,295 $10.8 Million
Q2 2019

Aug 14, 2019
BUY
$21.47 - $37.33 $2.35 Million - $4.08 Million
109,255 Added 13.46%
921,121 $20.8 Million
Q1 2019

May 15, 2019
BUY
$28.4 - $36.49 $4.92 Million - $6.32 Million
173,194 Added 27.12%
811,866 $29.6 Million
Q4 2018

Feb 15, 2019
BUY
$27.94 - $44.61 $1.03 Million - $1.64 Million
36,760 Added 6.11%
638,672 $18.8 Million
Q3 2018

Nov 20, 2018
SELL
$38.6 - $46.12 $104,374 - $124,708
-2,704 Reduced 0.45%
601,912 $25.5 Million
Q2 2018

Aug 10, 2018
SELL
$40.56 - $51.36 $1.13 Million - $1.42 Million
-27,741 Reduced 4.39%
604,616 $24.9 Million
Q1 2018

May 17, 2018
SELL
$53.61 - $67.26 $933,671 - $1.17 Million
-17,416 Reduced 2.68%
632,357 $36.7 Million
Q4 2017

Feb 13, 2018
BUY
$47.69 - $55.39 $31 Million - $36 Million
649,773
649,773 $35.6 Million

Others Institutions Holding ALKS

# of Institutions
360
Shares Held
181M
Call Options Held
175K
Put Options Held
96.6K
View Full List

About Alkermes plc.

ALKS Quotes by TradingView
  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.63B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email